cyrilzakka/clinical-trials huggingface dataset:
Intranasal Desmopressin vs IV Ketorolac in Renal Colic Pain Control

The aim of this study is the comparison of efficacy of intravenous ketorolac and intranasal desmopressin in renal colic patients pain control.

40 renal colic patients have been divided into 2 groups randomly, one group has been received 30mg intravenous Ketorolac and 4 puffs nasal Normal Saline while other has been received 40 micrograms nasal Desmopressin and 1cc intravenous Normal Saline. Pain Score before drug administration,also 10, 30 and 60 minutes after drug administration has been measured bye Visual Analogue Scale ( VAS ).

Eligibility Criteria:
Inclusion Criteria:

* renal colic patients

Exclusion Criteria:

* history of hypertension and cardiac disease
* pregnant patients
* use of analgesic within 4 hours before intervention
Tele-Exercise for Male Elite Fencers

Tele-exercise has been used to enhance athletic performance among athletes. Physical performance indicators such as lunge distance, speed, reaction time, coordination, and balance control during stationary jumps can be used to measure the effectiveness of tele-exercise programs for fencing athletes.

The objective of this study was to examine the effectiveness of tele-exercise programs on lunge distance, speed, reaction time, coordination, and balance control during stationary jumps among male elite fencers.


Eligibility Criteria:
Inclusion Criteria:

* who are registered to Elite Fencer to both Korean Sports \& Olympic Committee and Korean Fencing Federation;
* who does not have a history of musculoskeletal or neurological injuries in the past six months;
* who have no physical limitations.

Exclusion Criteria:

* Those who have the experience of participating in experiments in the past year
* who refuses to participate or provide written consent.
The Viscoelastic Properties of Lower Extremity's Muscles

This study aims to create normative values for stiffness, tonus and elasticity in the lower extremity muscles and to determine age and gender differences.


Eligibility Criteria:
Inclusion Criteria:

* Individuals without any systemic or metabolic diseases, psychological illnesses, or drug abuse; those without any diseases that could cause muscle disease or muscle atrophy; and those who had not undergone any surgery in the musculoskeletal system during the past 3 months were included

Exclusion Criteria:

-
Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention

The purpose of this study is to investigate the effect of cilostazol loading before planned PCI on major adverse cardiac and cerebrovascular events in patients with coronary artery disease.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing elective PCI
* Presence of coronary lesions amenable to stent

Exclusion Criteria:

* Cardiogenic shock
* Urgent PCI
* Hypersensitivity to aspirin, clopidogrel, or cilostazol
* LVEF \< 30% or congestive heart failure
* Bleeding diathesis
* leukocyte count \< 3,000/mm3 and/or platelet count \< 100,000/mm3
* aspartate aminotransferase or alanine aminotransferase \> 3 times upper normal; serum creatinine \> 2.0 mg/dl
* noncardiac disease with a life expectancy \< 1 year
* inability to follow the protocol
Effect of PF-00734200 in Subjects With Type 2 Diabetes

To determine the effect of PF-00734200 on HbA1c in type 2 diabetic subjects receiving metformin


Eligibility Criteria:
Inclusion Criteria:

Men or women between 18-80 years of age with poorly controlled Type 2 diabetes

Exclusion Criteria:

Type 1 or secondary forms of diabetes Currently using insulin
Randomized Study of Two Interventions for Liquid Aspiration: Short-Term and Long-Term Effects

The purpose of this study is to determine whether chin-down posture or use of a thickened liquid diet is more effective in the prevention of aspiration and aspiration pneumonia in patients with Parkinson's disease and/or dementia. Liquid aspiration is the most common type of aspiration in older populations, especially those suffering from debilitation, dementia, and depression. Pneumonia may develop as a consequence of aspiration and is the fifth leading cause of death in the US among persons age 65 years and over. Current treatment involves either use of chin-down position with swallowing or use of thickened liquids in the diet, without any clear evidence supporting the use of one treatment over the other. This is a Phase III inpatient and/or outpatient study in which all participants will be randomly assigned to either the chin-down position or the thickened liquid treatment group based on swallowing function during a modified barium swallow. This study is scheduled to recruit patients for a three-year period; participation by each individual patient spans no more than three months after entry.


Eligibility Criteria:
Inclusion Criteria:

* Have dementia or Parkinson's disease and are found to aspirate on thin liquid during a set of qualifying swallows.

Exclusion Criteria:

* Have smoked more than a pack of cigarettes per day in the last year.
* Drink more than 3 alcoholic beverages per day on a regular basis.
* Have had any head and neck cancer treatment.
* Have any head and neck anatomic deformities.
* Have a history of 20 years or longer of insulin-dependent diabetes.
* Have other exclusionary neurologic diagnoses.
* Have had pneumonia within 6 weeks of screening.
* Currently have a nasogastric tube.
* Currently have a tracheotomy.
* Are a resident in non-participating nursing home or assisted living environment.
* Live alone.
* Have no regular care provider present at meals.
* Have no Speech-Language Pathologist to provide a 3-month follow-up.
A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes

The main objectives of the current study are to establish the safety and clinical proof-of-concept of NC-503 in inadequately controlled patients with Type 2 diabetes and features of metabolic syndrome treated with either metformin, a sulfonylurea agent, or metformin in combination with a sulfonylurea agent.

Phase IIa Multi-center, randomized, double-blind, placebo-controlled and parallel-designed study.

Eligibility Criteria:
Inclusion Criteria:

* Age and gender eligibility: 30 years and older
* Diagnosis of Type 2 diabetes mellitus
* Patients treated with a stable therapeutic dose of either metformin, a sulfonylurea agent, or metformin in combination with a sulfonylurea agent for a minimum period of 3 months prior to the Screening visit
* Patients must have HbA1C level between 7.0-10.0 %, inclusively at screening
* The participant must have central obesity (Waist circumference) defined per country/ethnic group: Europids: men ≥ 94 cm, women ≥ 80 cm; South Asian, Chinese \& Japanese: men ≥ 90 cm, women ≥ 80 cm; and any one of the following metabolic syndrome characteristics at screening:
* Reduced HDL cholesterol ≤ 1.0 mmol/L
* Hypertriglyceridemia ≥ 1.7 mmol/L or treatment for dyslipidemia
* Hypertension: ≥ 130/85 mm Hg blood pressure or treatment with antihypertensive medication.
* Patients must have a Glomerular Filtration Rate (GFR) of ≥ 60 mL/min, and no history of dialysis.

Exclusion Criteria:

* Patients having received insulin, thiazolidinediones (TZDs) or non-thiazolidinedione hypoglycemic agents other than metformin or sulfonylurea agents within three months prior to screening
* Has had, within the last 6 months, evidence of significant heart disease or stroke, including myocardial infarction, unstable angina, coronary bypass and/or percutaneous transluminal coronary angioplasty (PTCA), congestive heart failure (New York Heart Association Class III-IV), or severe ischemic disease
* Patients who have an increased red blood cell (RBC) turn-over or Thalassemia or anemia
* Known HIV or history of viral hepatitis type B or C.
* Any type of diabetes other than Type 2 diabetes
* Significant hepatic enzyme elevation
* Body mass index (BMI) of \> 40kg/m2
* Current or previous use of oral or injectable corticosteroids, or conditions that require the use of corticosteroids, during the three months prior to screening
Analysis of Biomarkers in Lymph Node Tissue

Researchers are doing an exploratory analysis of biomarkers to correlate with treatment outcome of transplant surgery.

Researchers will study previously collected tissue, which was sent for pathological examination, of 200 patients who underwent transplant surgery. Concentration of biomarkers in lymph node tissue will be measured.

Eligibility Criteria:
Inclusion Criteria:

* Adults (18+years of age)
* Undergo any organ transplant

Exclusion Criteria:

* Under the age of 18 years old
A Retrospective Cone Beam Computed Tomography Study of The Lateral Wall Bony Window

Three experienced observers were asked to screen all the CBCT images from the Stomatology Hospital,Zhejiang University School of Medicine, between September 1, 2019 and December 31, 2019, and counted 1000 maxillary sinus CBCT images that met the criteria. Later, 1000 CBCT images were further measured and analyzed, and indicators such as maxillary sinus buccal wall thickness, morphology, whether there is blood vessel or not, whether there is bone septa or not were counted. The variation rules and related factors were summarized by SPSS analysis.


Eligibility Criteria:
Inclusion Criteria:

* Images were included if the following criteria were met: (1) patients were 18 years or older, (2) presence of teeth adjacent to or opposing the edentulous area allowing the location of the edentulous ridges corresponding to the tooth site to be identified, (3) presence of maxillary dentition defect in any tooth positon of the second premolar, the first molar or the second molar, (4) the maxillary sinus to be measured was visible from its floor to at least 15 mm high.

Exclusion Criteria:

* Images were excluded if any of the following criteria were met: (1) images were unclear or incomplete due to scattering or other reasons, (2) pristine maxillary posterior extraction sites after less than 3 months of healing and the tooth extraction sockets could be obviously identified, (3) the maxillary sinus had been grafted for implant-supported prosthesis, (4) implants or other prosthetic devices were present in maxillary posterior edentulous position, (5) orthodontic brackets and wires in images were present; (6) the location of the edentulous sites could not be determined, (7) sinus pathology was present that made the measurement impossible.
Management of Proximal Humerus Fractures in Adults: a Clinical Trial

Prospective patient registry examining the outcome of three different treatment methods for proximal humerus fractures in elderlies: conservative treatment, open and minimal invasive surgical treatment.

The present study shall be conducted in accordance with the SPIRIT 2013 statement: defining standard protocol items for clinical trials. All patients who sustained a PHF and presented at the Department of Orthopedics at the Academic Hospital of Bolzano (Italy) will be prospectively incited to participate in the present clinical trial. Patient recruitment will begin in April 2024, and end in April 2026. The follow-up period will start in October 2024, and end in April 2028. Data analysis will commence in October 2024 and end in April 2028. The present study shall be conducted according to the principles of the Declaration of Helsinki. The authors receive no financial support for the research, authorship, and/or publication of this article. The protocol of the study has been prospectively registered and approved by the German Registry of Clinical Trials (ID DRKS00030614). Ethics approval has been received from the Ethic Committee of the South Tyrolean Health Authority, Bolzano, Italy (ID 2022374 of June 22, 2023). All surgical and conservative procedures under analysis are already routinely carried out at the Department of Orthopaedics and Trauma Surgery of the Academic Hospital of Bolzano, Italy. Patients who meet the inclusion criteria and agree to participate in the study by signing the consent form and the personal data processing form will be included in the study.

Data curation Personal data, including sensitive data, will be pseudonymised and associated with a code from which it will be impossible to trace the patient's identity. Only the Principal Investigator and sub-investigators of the study will be able to link the code to the name. The pseudonymised data will be collected in a table of Microsoft Office Excel version 16 (Microsoft Corporation, Redmond, US).

Statistical analyses Assuming an actual difference in means between the test and reference group of 3 units and a pooled standard deviation of 5 units, the study would require a sample size of 117 patients for each group (i.e. a total sample size of 351, assuming equal group size), to obtain a power of 80% and a significance level of 5%, to declare the superiority of a technique with a margin of prominence of 5 units, assuming a minimum clinically important difference OSS of 2.7/100 .

Eligibility Criteria:
Inclusion Criteria:

1. adults who sustained a Proximal Humerus Fracture within the last week
2. type of Proximal Humerus Fracture AO 11-(A2, A3), 11- (B1, B2, B3)
3. BMI lower than 40 Kg/m2

Exclusion Criteria:

1. stress fractures
2. revision setting
3. open fractures
4. fractures associated with a neurologic lesion; previous fractures or bony procedure at the homolateral side
5. patients unable to understand the procedure or instructions for rehabilitation
6. terminal patients
7. patients presenting multiple injuries
Advanced Radiotherapy (ART) in Prostate Cancer (PROST-ART)

This is a retrospective monoinstitutional study which analyses the results of advanced radiotherapy (IGRT, IMRT, SBRT, and PET-guided) performed for radical, adjuvant, or salvage purposes in patients with low, intermediate, high, and very high-risk prostate cancer, or with biochemical, lymph node, or oligometastatic recurrence treated between 2004 and 2024.

Approved by Ethics Committee of IRCCS San Raffaele Hospital Approval Number: 187/INT/2021, 03/02/2022

Amendment approved by Ethics Committee 1, Lombardy Region Approval number CET Em. 194-2024, 22/05/2024

This is a single-center, retrospective study (PROST-ART) that has as its primary objective the evaluation of the efficacy of radiotherapy treatments performed in patients with early-stage, advanced, metastatic prostate disease, with biochemical relapses after surgery, with local relapses after radiotherapy, or oligometastatic/oligoprogressive disease. The aim of the study is to measure the biochemical relapse-free survival (bRFS), local and regional relapse (LR, regional relapse, RR), distant metastases-free survival (DMS), clinical relapse (DFS), disease-free survival (PCSS), and overall survival (OS) from both disease diagnosis and the end of radiotherapy until the last useful follow-up, or until the patient's death. In addition, the acute and late toxicity of treatments will be assessed from the start of treatment until the last follow-up/death of the patient and the period without other oncological treatments, from the end of treatment until the start of another oncological treatment/last follow-up.

At least 200 patients treated in the last 5 years, some receiving stereotactic radiotherapy to the prostate, or prostate and seminal vesicles, and the others pelvic lymph node and prostate irradiation, who are still alive and contactable, and agree to participate, will be included in a survey on quality of life (QoL). These patients, after signing an informed consent for the collection of new information, will receive an EORTC QLQ-PR25 quality of life questionnaire, in order to quantify the impact of toxicity. In addition, the radiomic characteristics of the computed tomography/ PET-CT performed for treatment planning along with evaluation of the results will be extracted to identify related predictive factors.

The QoL study is configured as retrospective as the questionnaire will only be an expression, from the patient's point of view, of the toxicity of the previous treatment.

Eligibility Criteria:
Inclusion Criteria:

* Prostate cancer patients, \> 18 years old, treated with IGRT, IMRT, SBRT

Exclusion Criteria:

* other tumors
* \> 95 years old
A Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy Subjects

This is a randomised, cross-over study comprised of 6 periods in healthy subjects.Subjects will receive Regimens A, B and C in a randomised crossover manner in the fed state, followed by Regimens D, E and F in a randomised crossover manner, in the fasted or fed state, as applicable.

This is a single centre, randomised, cross-over study comprised of 6 periods in healthy males and females.Subjects will receive Regimens A, B and C in a randomised crossover manner in the fed state, followed by Regimens D, E and F in a randomised crossover manner, in the fasted or fed state, as applicable.

Eligibility Criteria:
Inclusion Criteria:

* Healthy male and non-pregnant, non-lactating female subjects
* Aged 18 to 55 years
* Body mass index of 18.0 to 32.0 kg/m2
* Must agree to the use of an adequate method of contraception

Exclusion Criteria:

* Subjects who have received any IMP in a clinical research study within the previous 3 months
* History of any drug or alcohol abuse in the past 2 years
* Current smokers and those who have smoked within the last 12 months.
* Alkaline phosphatase, aspartate aminotransferase and/or alanine aminotransferase level \>1.5 x upper limit of normal at screening
* Abnormal renal function at screening
* Clinically significant abnormal biochemistry, haematology, coagulation profile or urinalysis
* Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
* History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or GI disease, neurological or psychiatric disorder.
* Subjects with a history of gall stones or abdominal surgery eg cholecystectomy
* Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
* Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedy (including known inhibitors or inducers of CYP3A4
Study on Early Lyme Neuroborreliosis

The purpose of this study is to determine clinical course and the sequelae of early Lyme neuroborreliosis after treatment with ceftriaxone.


Eligibility Criteria:
Inclusion Criteria:

* erythema migrans within 4 months before neurologic involvement and pleocytosis in patients \>15 years old

Exclusion Criteria:

* pregnancy
* lactation
* history of adverse reaction to a beta-lactam antibiotic
Unilateral Approach for Bilateral Decompression of Lumbar Canal Stenosis

The purpose of this study was to compare standard open laminectomy with ULBD approach in regard to efficiency, safety, and clinical outcome.

Lumbar stenosis is one of the common spinal pathologies; it presents with back pain, leg pain, and neurogenic claudication . Although different surgical modalities are available, the main objective of the operation is decompression of nerve roots and the spinal cord.

Minimally invasive surgical procedures and microsurgical unilateral laminotomy with bilateral spinal canal decompression (ULBD) have been reported to achieve this goal .

The objective of lumbar decompression is to decompress the neural elements while preserving stability and the spinous processes.

The object of this study is to compare outcomes following minimally invasive unilateral laminectomy for bilateral decompression (ULBD) to a standard "open" laminectomy for LSS.

Eligibility Criteria:
Inclusion Criteria:

1. age:40-80 years
2. sex:both sexes
3. symptomatic LSS with radiculopathy , neurogenic claudication , or urinary dysfunction.
4. radiologically confirmed LSS , caused by degenerative changes
5. canal stenosis at a maximum of 2 levels

Exclusion Criteria:

1. were to undergo a concomitant fusion or instrumentation placement;
2. had had previous lumbar surgeries at the same level;
3. had spondylolisthesis of any grade or degenerative scoliosis;
4. had evidence of instability on dynamic radiographs.
Prevalence and Risk Factors for Common Diseases

By using national databases in Sweden the aim of the present project is to:

1. Investigate if the incidence of our most common diseases, such as fracture and cardiovascular disease, has changed from 1970-2017
2. To investigate whether the risk of death for our most common diseases have changed from 1970-2017.
3. To investigate the risk of a new episode after suffering from our most common diseases from 1970-2017
4. To investigate the risk factors for our most common diseases, and whether these have changed from 1970.
5. To investigate how severe disease or death affects the health of a close relative.

Please see above on the summary.

Eligibility Criteria:
Inclusion Criteria:

* All people living in Sweden that is diagnosed with our most common diseases between 1970-2017.

Exclusion Criteria:

* None
Prophylactic Acetaminophen for Prevention Intraventricular Hemorrhage in Premature Infants

The purpose of this study is to determine whether acetaminophen is effective in prevention or reducing the severity of IVH in premature infants.

It will be a double-blind randomized control trial, single center. The study will include neonates with a gestational age of less than or equal 32 weeks and a birth weight of less than or equal 1500 g, and will randomly assigned to two treatment groups (see below).

Infants will be randomized to equal-sized groups using block randomization with blocks of four. Stratified randomization for gender and gestational age will be included in the randomized blocks. Gestational age will be divided into two categories: 23 weeks +0 day to 27 weeks +6 days, and from 28 weeks +0 day to 32 weeks +6 days. Gender (2) × gestational age (2) will give 6 strata, requiring 6 separate random number lists to achieve randomization.

Eligibility Criteria:
Inclusion Criteria:

* Premature baby less than or equal 32 week and birth weight less than or equal 1500 g

Exclusion Criteria:

* Out-born babies, infants with major congenital anomalies, babies have IVH III, IV, High expectancy of early death